Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 3/20 | 0.31 |
| ▸ | BRAF | P15056 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19687275 | 0.95 | IDH1 (0.34) | IDH1ATRGPR119RAF1BRAF | |
| SCHEMBL19687466 | 0.91 | PIK3R2 (0.32) | IDH1ATRGPR119RAF1BRAF | |
| SCHEMBL21166046 | 0.90 | IDH1 (0.40) | IDH1GPR119RAF1BRAF | |
| SCHEMBL19687270 | 0.89 | GPR119 (0.31) | IDH1ATRGPR119 | |
| SCHEMBL19687237 | 0.89 | GPR119 (0.33) | IDH1ATRGPR119RAF1 | |
| SCHEMBL19686597 | 0.89 | GPR119 (0.31) | ATRGPR119 | |
| SCHEMBL21144074 | 0.88 | IDH1 (0.43) | IDH1ATRRAF1BRAF | |
| SCHEMBL19687239 | 0.86 | PIK3CA (0.36) | RAF1BRAF | |
| SCHEMBL21144017 | 0.84 | P2RX3 (0.36) | RAF1BRAF | |
| SCHEMBL21143613 | 0.83 | IDH1 (0.36) | IDH1ATRRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885ATR 4491/4885GPR119 236/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885ATR 4491/4885GPR119 236/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885ATR 4491/4885GPR119 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.